Prosecution Insights
Last updated: November 04, 2026
Application No. 16/770,497

ORGANIC-INORGANIC COMPLEX, MANUFACTURING METHOD THEREOF AND UV BLOCKING AGENTS USING THE SAME

Non-Final OA §103
Filed
Jun 05, 2020
Priority
Dec 06, 2017 — RE 10-2017-0166762 +2 more
Examiner
YU, HONG
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sera Soo Co. Ltd.
OA Round
9 (Non-Final)
31%
Grant Probability
At Risk
9-10
OA Rounds
0m
Est. Remaining
37%
With Interview

Examiner Intelligence

Grants only 31% of cases
31%
Career Allowance Rate
218 granted / 701 resolved
-28.9% vs TC avg
Moderate +6% lift
Without
With
+5.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
49 currently pending
Career history
777
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
51.5%
+11.5% vs TC avg
§102
18.5%
-21.5% vs TC avg
§112
16.5%
-23.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 701 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. DETAILED ACTION Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 06/29/2026 has been entered. Rejections withdrawn Applicant’s amendments and arguments filed on 06/29/2026 are acknowledged and have been fully considered. Any rejection and/or objection not specifically addressed below is herein withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set of rejections and/or objections presently being applied to the instant application. Rejections maintained The following rejection of the claims is maintained for reasons of record and the following. The rejection is modified based on the amendments. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1 and 2 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gonzalez et al. (US 2010/0184887 A1) in view of Samain et al. (US 2012/0328542 A1). Gonzalez et al. teach particles P (being X-Y-Z) of inorganic nanoparticles with ZnO being inorganic nanoparticle X having particle size of 1-20 nm (the claimed M) (paragraph 47), with organic molecules M being Y-Z and with Y being a silane (crosslinked) (paragraph 62) linker and Z being a chromophore UV absorber including benzylidenecamphor or its derivatives including 3-Benzylidenecamphor (abstract, paragraph 38, 42, 49, 51, 60-63, 65, and 71); and the coverage of M of P (i.e., on X) being partial (paragraph 44) and M being 5-70% by weight of P (paragraph 45); and exemplified ZnO (X) with silane linker 3-aminopropyltriethoxysilane (Y, PNG media_image1.png 101 282 media_image1.png Greyscale i.e., R1 and R2 being hydrogen and R3 being C3 alkyl in the middle component of claimed formula 1-1) and 1:1 molar ratio between ZnO (X) and silane linker (Y) in example 2 and a particle formed from ZnO (X) reacting with silane linker (Y)-cyanoacrylamide chromophore of example 4 in example 6. Gonzalez et al. teach X (the claimed M) and Y (silane linker, the claimed middle component in formula 1-1) being covalently bonded (paragraph 51, 60, and 90). With X and Y taught by Gonzalez et al. being the same as the claimed M and the claimed middle component in formula 1-1, respectively, the bond between X and Y taught by Gonzalez et al. would be the same type as the claimed bond between the claimed M and the claimed middle component in formula 1-1. Based on the teaching of the coverage of M on X being partial, M being 5-70% by weight of P, a particle in example 6 being formed from ZnO (X) reacting with silane linker (Y)-cyanoacrylate chromophore of example 4, silane linker (Y)-cyanoacrylamide chromophore portion weight of 359 g/mol (silane linker portion weight of 127 g/mol and cyanoacrylamide chromophore portion weight of 232 g/mol), the Y (silane in molar) (the claimed m in mmolar) relative to X (ZnO) in gram (the claimed M in g) is calculated to be 0.147-6.5 mmol / 1 g of ZnO (5x1000/359 : (100-5) → 0.147 : 1 and 70x1000/359 : (100-70) → 6.5 : 1). Gonzalez et al. do not specify benzylidenecamphor derivatives including terephthalylidene dicamphor sulfonic acid (the claimed left component in formula 1-1). This deficiency is cured by Samain et al. who teach organic UV screening agents benzylidenecamphor derivatives including 3-benzylidenecamphor, terephthalylidene dicamphor sulfonic acid ( PNG media_image2.png 411 983 media_image2.png Greyscale ) (paragraph 85, 86, and 99). It would have been prima facie obvious at the time of the invention to a person of ordinary skill in the art to combine the teachings in Gonzalez et al. and Samain et al. to replace 3-benzylidenecamphor in the particle taught by Gonzalez et al. with terephthalylidene dicamphor sulfonic acid. Both 3-benzylidenecamphor and terephthalylidene dicamphor sulfonic acid being organic UV screening agents benzylidenecamphor derivatives was well known to a person of ordinary skill in the art at the time of the invention. The motivation for replacing 3-benzylidenecamphor with benzylidenecamphor derivatives flows from both having been used in the prior art, and from both being recognized in the prior art as useful for the same purpose. Gonzalez et al. do not specify the same m in mmol (the Y, silane) relative to M (X, ZnO) in gram (0.147-6.5 mmol / 1 g vs the claimed 0.3-1.0 mmol / 1 g). This deficiency is cured by the rationale that a prima facie case of obviousness typically exists when the range of a claimed composition lies inside the range disclosed in the prior art, such as in the instant rejection. The claimed range of m in mmol relative to M in gram is 0.3-1.0 mmol / 1 g and the range of Y (silane) in mmol relative to X (ZnO) in gram taught in the prior art is 0.147-6.5 mmol / 1 g and therefor, includes the claimed range. Gonzalez et al. do not specify the same ZnO particle size (1-20 nm vs the claimed 10-80 nm in the instant claim 1). The limitations of TiO2 and SiO2 particle sizes in the instant claim 1 are further limitations of alternative components. This deficiency is cured by the rationale that a prima facie case of obviousness typically exists when the range of a claimed composition overlaps with the range disclosed in the prior art, such as in the instant rejection. The claimed range of ZnO particle size is 10-80 nm and the range of ZnO particle size taught in the prior art is 1-20 nm and therefor, overlaps with the claimed range. Response to Applicants’ arguments: Applicant’s argument based on the amendments is addressed in the modified rejection above (newly underlined). Applicant’s argument of the claimed complex sulfonate group(s) of the TDSA moiety being ironically associated with the cationic ammonium group of the silane compound and Gonzalez et al. not teaching ionic bond between Y and Z is basically the same as the arguments dated 02/21/2023, 07/28/2023, 03/10/2024, 09/26/2024, and 05/21//2025, thus the responses discussed previously in the office actions dated 03/30/2023 (page 3-5), 10/10/2023 (page 5-7), 04/10/2024 (page 5-6), 11/22/2024 (page 4-5), and 06/04/2025 (page 6-7) apply here as well and are not persuasive for reason discussed previously. Applicant’s argue of Samain et al. not teaching the claimed complex is basically the same as the arguments dated 02/21/2023 and 05/21/2025 thus the response discussed previously in the office action dated 03/30/2023 (page 5) and 06/04/2025 (page 7) applies here as well and is not persuasive for reason discussed previously. Applicants argue that it requires hindsight reasoning to arrive at the claimed complex. However, this argument is not deemed persuasive. In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). In the instant case, Gonzalez et al. teach Z in X-Y-Z being a chromophore UV absorber including benzylidenecamphor or its derivatives including 3-Benzylidenecamphor (the claimed left component in formula 1-1) while Samain et al. provide teaching of organic UV screening agents benzylidenecamphor derivatives including 3-benzylidenecamphor, terephthalylidene dicamphor sulfonic acid ( PNG media_image2.png 411 983 media_image2.png Greyscale ). It would have been prima facie obvious at the time of the invention to a person of ordinary skill in the art to combine the teachings in Gonzalez et al. and Samain et al. to replace 3-benzylidenecamphor in the particle taught by Gonzalez et al. with terephthalylidene dicamphor sulfonic acid. Applicant’s argument of the claimed 0.3-1.0 mmol / 1 g is much narrower than the calculated 0.147-6.5 mmol / 1 g from Gonzalez et al.’s teaching is basically the same as the argument dated 12/01/2025 thus the response discussed previously in the office action dated 01/30/2026 (page 7-8) applies here as well and is not persuasive for reason discussed previously. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to HONG YU whose telephone number is (571)270-1328. The examiner can normally be reached on 9 am - 5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, Applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached on 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HONG YU/ Primary Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

Show 14 earlier events
May 21, 2025
Request for Continued Examination
May 27, 2025
Response after Non-Final Action
Jun 04, 2025
Non-Final Rejection mailed — §103
Dec 01, 2025
Response Filed
Jan 30, 2026
Final Rejection mailed — §103
Jun 29, 2026
Request for Continued Examination
Jun 30, 2026
Response after Non-Final Action
Oct 29, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12741055
NOVEL POLYSACCHARIDE-BASED HYDROGEL SCAFFOLDS FOR WOUND CARE
4y 10m to grant Granted Sep 22, 2026
Patent 12721861
DELIVERY AND RETENTION OF ACTIVE AGENTS WITHIN THE SKIN
4y 11m to grant Granted Sep 01, 2026
Patent 12721929
COMPOSITION USING FIBROTIC ACELLULAR DERMAL MATRIX, AND METHOD FOR PREPARING SAME
2y 8m to grant Granted Sep 01, 2026
Patent 12653185
MICROCAPSULES ENCAPSULATING LAMBDA-CYHALOTHRIN
7y 5m to grant Granted Jun 16, 2026
Patent 12648896
EMULSION COSMETIC
5y 4m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

9-10
Expected OA Rounds
31%
Grant Probability
37%
With Interview (+5.8%)
3y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 701 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month